Grey Matters Health Inc · CSE:GREY
Grey Matters Health — Investor Presentation (May 2026)
35 slides from Grey Matters Health's investor presentation, May 12, 2026
Slide 1: Investor Presentation
INVESTOR PRESENTATION CSE : GREY | OTCQB : AGNPF | XFRA : AGNW0
Slide 2: Disclaimer
DISCLAIMER Certain statements in this presentation (the “Presentation”) are forward-looking statements, which are made as of the date of this Presentation or as of the date of the effective date of information described in this presentation, as applicable. Forward-looking statements relate to future
Slide 3: Diagnosing Alzheimer's Disease with Brain Optimized PET Scans
Diagnosing Alzheimer’s Disease with Brain Optimized PET Scans Capturing a US$6.9 Billion Emerging Market 1 3
Slide 4: Alzheimer's Disease
Alzheimer’s Disease • Alzheimer’s (AD), the most common form of dementia, is a chronic neurodegenerative disease that destroys brain cells • Results in the steady decline over years of a person’s thinking ability and memory • Devastatingly affects an estimated 7 million Americans and 750,000 Canadia
Slide 5: Why Focus on Alzheimer's?
Why Focus on Alzheimer’s? • 7M Americans with AD increasing to 13M by 20505 AD begins with a buildup of beta-amyloid plaques • AD has generally not been diagnosed until and neurofibrillary tangles in the brain cognitive dysfunction is observed • Early detection can now be made 15-20 years before sym
Slide 6: Critical New AD Developments
Critical New AD Developments • Blood tests can now screen for changes in AD biomarkers years before symptoms appear and before irreversible brain damage occurs • The FDA has cleared a new compact brain scanner that confirms plaque presence • The FDA has also approved two new monoclonal antibody trea
Slide 7: Power of Brain PET Scanning
Power of Brain PET Scanning • Positron Emission Tomography (PET) brain scanning is used to confirm a diagnosis of AD • A radioactive tracer is injected into a patient’s bloodstream, which then travels to the brain and binds specifically to beta-amyloid plaques, making them visible on a PET scanner •
Slide 8: New FDA-Approved Monoclonal Antibody Therapies
New FDA-Approved Monoclonal Antibody Therapies Leqembi (Eisai and Biogen) • FDA-Approved 2023 • Given by twice/monthly infusion • US$26,500/year: U.S. Medicare/Medicaid/PI covered Kisunla (Eli Lilly) • FDA-Approved 2024 • Given by monthly infusion • US$32,000/year: U.S. Medicare/Medicaid/PI covered
Slide 9: Milestone PET Scan Announcement
Milestone PET Scan Announcement “A Profound Opportunity.” GE HealthCare CEO, Peter Arduini Note: Comment made in a 2024 GE HealthCare post-earnings call, reflecting on the potential market impact of the expansion of PET brain scans. Monoclonal anti-body treatment course requires multiple PET brain s
Slide 10: Addressable Alzheimer's Market
Addressable Alzheimer’s Market • Prior to approved antibody therapies, no urgent clinical need for AD confirmation • Massive gaps in diagnosis and treatment are now projected as more people get tested, putting pressure on current medical resources • 7 million in U.S. living with AD, and this is expe
Slide 11: Current Neuroimaging Technology – PET/CT Hybrid
Current Neuroimaging Technology – PET/CT Hybrid Equipment Cost US$3M – US$5M Install (HVAC & Electrical) US$250,000 Lead Shielding US$100,000CareMiBrain costs Restrictions (Size/Weight) PET/CT Scanner (Positron Emission Tomography) – Baptist Health Large Footprint and Heavy - Up to 11,000 lbs. fully
Slide 12: PET/CT Scanner Overview in U.S.
PET/CT Scanner Overview in U.S. • 50% of scanners are in U.S. hospitals; hard to access • 75% of imaging time is prioritized for cancer diagnostics and theranostics (extensive waiting times - months) • 15% of imaging time is also prioritized for cardiac imaging • Unable to turn off CT scan (not requ
Slide 13: Imaging Centers Prefer Body Over Brain PET/CT Scans
Imaging Centers Prefer Body Over Brain PET/CT Scans • Whole body PET/CT scans offer high patient volume with standard tracers for common cancer and heart imaging • Brain scans are a smaller segment requiring longer set- up, specialized tracers, and advanced technical expertise • Brain PET scanning i
Slide 14: U.S. PET/CT Market
U.S. PET/CT Market • Cumulative Total: PET/CT Scans in U.S. (2020-2024) $5.33 billion • Growth Factors: Rising Alzheimer's prevalence (projected 139 million global cases by 2050) and 2023– 2024 Medicare expansions boosted utilization by 20 - 40% in neurology. • New dedicated brain PET devices will a
Slide 15: Grey Matters' Market Vision
Grey Matters’ Market Vision • Establish a new, national network of private U.S. neuroimaging medical clinics, dedicated to offering FDA-cleared brain specific, neuro optimized PET scanning technology for detection of Alzheimer's Disease, and… - Epilepsy - Parkinson’s - Multiple Sclerosis - Brain Can
Slide 16: Grey Matters' Branding for Alzheimer's Initiative
Grey Matters’ Branding for Alzheimer’s Initiative 16
Slide 17: NovaScan Neuroimaging Clinics Technology
NovaScan Neuroimaging ClinicsTM Technology • The CareMiBrainTM PET Brain Scanning System • 25% Less Radiation (No CT Scan) • FDA-cleared in 2024: CE Mark for Europe • Ultra Compact (662lbs); high-resolution imaging chair • Standard Wall Outlet Power (115–240V), Low Heat Generation; quiet operation •
Slide 18: Patient Acquisition Targets/Referral Sources
Patient Acquisition Targets/Referral Sources Neurologists 50% Geriatricians 131,434 practicing in the U.S. CRO Psychiatrists GP General PCP Public General Public 45-65 yrs 25% 104.7 million in the U.S. (Early Screening) PCP 15% Primary Care Physicians 260,687 practicing in the U.S. Specialist Referr
Slide 19: NovaScan Neuroimaging Clinics - Patient Journey
NovaScan Neuroimaging ClinicsTM - Patient Journey PATIENT PRESENTS TO DOCTOR WITH Primary Care Physicians and Step 1 COGNITIVE DYSFUNCTION SYMPTOMS geriatricians who refer patients to Neurologists or Psychiatrists DOCTOR RULES OUT CANCER WITH MRI; Doctors have a duty of care to rule Step 2 MAY ORDER
Slide 20: Geographic Location of First NovaScan Neuroimaging Clinic in U.S.
Geographic Location of First NovaScan Neuroimaging Clinic in U.S. Davie, Florida - 6M People Within One Hour’s Drive 20
Slide 21: First NovaScan Neuroimaging Clinics Location in U.S.
First NovaScan Neuroimaging ClinicsTM Location in U.S. HCA Florida University Medical Office Building, HCA Florida University Hospital Campus 21
Slide 22: HCA Florida University Location
HCA Florida University Location Floor Plan HCA Florida University Medical Office Building Suite 470 7630 SW 34th Manor Davie, Florida 33328 22
Slide 23: Neuroimaging Clinic Value Proposition
Neuroimaging Clinic Value Proposition Easily Accessible Leading Edge Proficient and Low Wait Times Scans at 25% Rapid Report Community Brain Optimized Accredited for Appointment Reduced Generation to Clinics PET Scanners Staff Scheduling Radiation Patient Doctors Beautifully FDA-cleared Nuclear Clin
Slide 24: NovaScan Neuroimaging Clinics Key Metrics
NovaScan Neuroimaging ClinicsTM Key Metrics Square Footage Average of 1,750 Capital Requirements US$1.1 M Includes - US$850 K for Scanner (80%) - US$250 K for Shielding, Furniture, Clinic Equipment/Supplies, Marketing, Working Capital (with fully built-out space) PET Scan Fee (scan & isotope) US$5,3
Slide 25: NovaScan Neuroimaging Clinics Key Metrics
NovaScan Neuroimaging ClinicsTM Key Metrics Staff 2 – Nuclear Medicine Technician/Reception Admin. Monthly Operating Costs US$70 K Daily Maximum # of Scans 15 Annual Maximum # of Scans 3,600 Clinic Break Even 1.6 scans per day 25
Slide 26: U.S. Imaging Company Comparables
U.S. Imaging Company Comparables Public: RadNet, Inc. (NASDAQ: RDNT) is the largest provider of freestanding, fixed-site outpatient diagnostic imaging in the U.S. with more than 400 centers. Market Cap: US$6 B Private: SimonMed Imaging outpatient medical imaging provider operating over 160 locations
Slide 27: NovaScan Neuroimaging Clinics Launch Partners
NovaScan Neuroimaging ClinicsTM Launch Partners Catalyst MedTech • Leading U.S. provider of molecular imaging and nuclear medicine technology to physician practices and healthcare systems • 500 employees with a nationwide presence • Exclusive distributor of the CareMiBrain PET brain specific scanner
Slide 28: NovaScan Neuroimaging Clinics Launch Partners
NovaScan Neuroimaging ClinicsTM Launch Partners American Molecular Imaging • A leading U.S. physician-owned and managed company specializing in teleradiology and theranostics services • AMI delivers specialized professional radiology interpretation, focusing on molecular imaging, nuclear medicine, a
Slide 29: NovaScan Neuroimaging Clinics Isotope Tracer Supply
NovaScan Neuroimaging ClinicsTM Isotope Tracer Supply GE HealthCare Technologies • Leading global health technology company involved in Medical Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. • A significant presence in the distribution space for radiotracers to help fac
Slide 30: Corporate Structure
Corporate Structure Grey Matters Health Inc. CSE : GREY | OTCQB : AGNPF | XFRA : AGNW0 Note: - 100% Owned Subsidiary In some U.S. states, where a physician- owned “Professional Corporation” is required to own the clinic, Grey Matters Health will provide management. Holdco LLC Direct Ownership - (Pri
Slide 31: Grey Matters Health Capitalization
Grey Matters Health Capitalization Capitalization Common Stock Equivalents NOTE: Not included in the capitalization table above are 1,983,601 Common Warrants (WAEP $2.95), 105,800 Stock Options (WAEP $0.97) and 111,269 Preferred Warrants (WAEP $15.000) as all have strike prices in excess of the rece
Slide 32: Grey Matters Health Management Team
Grey Matters Health Management Team Christopher J. Moreau James Kinley, CPA CA Chief Executive Officer Chief Financial Officer • President, CEO & director of a TSX:V listed R&D • Mr. Kinley is a Certified Professional Accountant (“CPA, company in the life sciences sector for over nine years CA”) wit
Slide 33: Grey Matters Health Board of Directors
Grey Matters Health Board of Directors Harry Bloomfield Christopher J. Moreau Dr. Raj Attariwala Howard Gutman Dr. Mark Williams KC, MBA CEO & Director MD, PhD, FANM, FRCP Ambassador (Rtd) PhD, MBA Chairman (co-founder of Prenuvo) Director Director Director 33
Slide 34: Key Attributions
Key Attributions 1. https://www.grandviewresearch.com/industry-analysis/us-alzheimers-linked-imaging-market-report 2. https://www.alz.org/alzheimers-dementia/facts-figures 3. https://alzheimer.ca/en/about-dementia/what-dementia/dementia-numbers-canada 4. https://www.ncbi.nlm.nih.gov/books/NBK618297/
Slide 35: Investor Presentation
INVESTOR PRESENTATION CSE : GREY | OTCQB : AGNPF | XFRA : AGNW0
Grey Matters Health — Investor Presentation (May 2026) on 6ix